Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. freshman Avg
|
New words:
absorb, acility, alefacept, Amevive, begun, Biogen, Bulletin, Chairman, channel, cyclosporin, distribution, DSO, emption, ESP, evolving, feature, foregoing, fr, GAAP, half, health, inability, Ju, labor, lack, largest, le, light, lowerthan, mber, methotrexate, milli, minimal, mix, mount, move, ngthy, nonrecourse, Nonrefundable, om, omitted, Omnitarg, paymen, pertuzumab, phototherapy, physician, plaque, psoriatic, read, reat, recourse, Red, SEC, Septe, settled, sil, silo, strial, ultraviolet, VIE, Wyeth, yi
Removed:
abciximab, allegedly, approvable, Article, breached, conceal, consisting, defendant, dismissed, duration, duty, execution, fiduciary, Green, growing, incomplete, individual, lengthy, mistrial, nature, necessarily, nominal, plaintiff, preventative, removed, ReoPro, returned, slightly, terminated, thereto, unaudited, Union, unspecified, withhold
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 15.1 Letter Regarding Unaudited Interim Financial Information
- 31.1 Certification of Chief Executive Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 31.2 Certification of Chief Financial Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 32.1 Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.s.c. Section 1350
Genentech similar filings
Filing view
External links